BetterLife Pharma Inc. (BETRF)
OTC Markets OTCQB
Fundamentals
Valuation and ratings
BetterLife Pharma Inc. trades at USD0.15. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About BetterLife Pharma Inc.
BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company offers a product pipeline that includes BETR-001, a non-hallucinogenic neuroplastogen based on 2-bromo-lysergic acid diethylamide (2-bromo-LSD), intended for the treatment of major depressive disorder, anxiety disorder, neuropathic pain, and other neuropsychiatric and neurological conditions. It is also developing MM-001, a topical cream formulation of interferon-alpha 2b, which has completed Phase II clinical trials for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation that has completed Phase II clinical trials for the treatment of COVID-19 and other respiratory viral infections. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.
The full research page for BETRF, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.